Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fenaux

Showing results (281-290 of 320) with videos related to

Pageof 32
Sort By:
Leukemia|July 1, 2017
Preclinical modeling of myelodysplastic syndromesK Rouault-Pierre, S A Mian, M Goulard, et al.
Leukemia Research|January 15, 2008
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideC Kelaidi, S Park, S Brechignac, et al.
Oncogene|April 29, 2009
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndromeS Boehrer, L Adès, N Tajeddine, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
Blood|November 9, 2018
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsU Platzbecker, P Fenaux, L Adès, et al.
Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.
Leukemia|February 1, 2012
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French AssociationA Renneville, N Boissel, O Nibourel, et al.
Leukemia|July 6, 2007
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialE Tavernier, J-M Boiron, F Huguet, et al.
Leukemia & Lymphoma|July 16, 2005
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapyX Thomas, Qh Le, S de Botton, et al.
Leukemia|May 13, 2005
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL GroupC Callens, S Chevret, J-M Cayuela, et al.
Pageof 32

Showing results (281-290 of 320) with videos related to

Sort By:
Pageof 32
Leukemia|July 1, 2017
Preclinical modeling of myelodysplastic syndromesK Rouault-Pierre, S A Mian, M Goulard, et al.
Leukemia Research|January 15, 2008
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideC Kelaidi, S Park, S Brechignac, et al.
Oncogene|April 29, 2009
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndromeS Boehrer, L Adès, N Tajeddine, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
Blood|November 9, 2018
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsU Platzbecker, P Fenaux, L Adès, et al.
Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.
Leukemia|February 1, 2012
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French AssociationA Renneville, N Boissel, O Nibourel, et al.
Leukemia|July 6, 2007
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialE Tavernier, J-M Boiron, F Huguet, et al.
Leukemia & Lymphoma|July 16, 2005
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapyX Thomas, Qh Le, S de Botton, et al.
Leukemia|May 13, 2005
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL GroupC Callens, S Chevret, J-M Cayuela, et al.
Pageof 32